Update (4:05 p.m.): Updated with Wednesday market close information.
IsoRay announced the world's first treatment of a tumor in a pediatric patient through the use of multiple Cesium-131 sutured seed meshes for internal radiation therapy. Dr. Anthony Crimaldi at Levine Cancer Institute in Charlotte successfully performed the implant using IsoRay Medical's Cesium-131 brachytherapy mesh.
The patient was a 12-year-old male with a type of childhood kidney tumor.
The stock closed at $2.54, up 133.03% or $1.45 from its previous close of $1.09, at the close of the trading day. It amassed a volume of 81,483,465, which dwarfs its average of 1,521,610.